Close X
Get more out of
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.

Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £3.50 an issue!

July 2020 (Vol. 5 Issue 5)

Research: when, and why, the money runs out
About the author: 

Research: when, and why, the money runs out image

Research is an essential ingredient of medicine

Research is an essential ingredient of medicine. Drugs and therapies can be evaluated and reconsidered, and better methods can be adopted as part of clinical practice.

But research can be a time-consuming - and expensive - process, and one that often needs a benefactor. Pharmaceutical companies are frequent sponsors of research trials, especially if they have a drug of their own that they want evaluating.

Sometimes he who pays the piper calls the tune, and we've come across examples in the past when results have been massaged, or the summary section altered, to show the benefactor's product in a better light.

This doesn't always happen, of course. Take the case of the CONVINCE trial, which failed to put forward a convincing case for the calcium-channel blocker verapamil, manufactured by GD Searle as Calan, and by other manufacturers under different brand names.

A pity really as GD Searle was the sponsor of the trial - and then suddenly withdrew its sponsorship before it was completed.

Up to the point the plug was pulled, the researchers found that verapamil was no better than other classes of heart drugs in preventing heart disease. The researchers, based at Rush University in Chicago, based their findings on 16,602 participants who were given either verapamil or atenolol or hydrochlorothiazide.

Searle refused to give a reason for their sudden withdrawal of sponsorship. Certainly ownership changed several times during the lifetime of the trial, from Searle to Monsanto, and to Pharmacia, but could it be they got wind of the findings? The researchers say not, but we will all have our own views, no doubt.

(Source: Journal of the American Medical Association, 2003; 289:2073-82).

You may also be interested in...

Support WDDTY

Help support us to hold the drugs companies, governments and the medical establishment accountable for what they do.


Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2020 WDDTY Publishing Ltd.
All Rights Reserved